Swiss National Bank Purchases 70,000 Shares of DexCom, Inc. $DXCM

Swiss National Bank lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,144,600 shares of the medical device company’s stock after purchasing an additional 70,000 shares during the period. Swiss National Bank’s holdings in DexCom were worth $71,881,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC lifted its holdings in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares during the period. Integrated Wealth Concepts LLC raised its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in DexCom by 1.4% in the second quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after acquiring an additional 258 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Trading Down 1.2%

NASDAQ DXCM opened at $74.75 on Wednesday. The firm has a market capitalization of $28.84 billion, a PE ratio of 31.94, a P/E/G ratio of 1.25 and a beta of 1.45. The stock’s 50 day moving average is $71.75 and its 200 day moving average is $68.86. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.32 earnings per share. Research analysts forecast that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 71,750 shares of company stock worth $5,163,241. 0.28% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on DXCM. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target on the stock in a report on Tuesday, March 24th. Stifel Nicolaus set a $90.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, June 5th. TD Cowen reaffirmed a “buy” rating and set a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Piper Sandler reaffirmed an “overweight” rating and set a $88.00 target price (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Finally, Benchmark reiterated a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $85.36.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.